Reuters logo
BRIEF-Upsher-Smith says parent co to manufacture migraine medication in Japan With AstraZeneca
October 30, 2017 / 4:36 PM / 2 months ago

BRIEF-Upsher-Smith says parent co to manufacture migraine medication in Japan With AstraZeneca

Oct 30 (Reuters) - Upsher-Smith Laboratories LLC:

* Upsher-Smith Laboratories says co’s parent Sawai Pharmaceutical entered agreement with AstraZeneca to manufacture & market migraine medication in Japan​

* Upsher-Smith Laboratories​ - agreement is to ‍manufacture, market Zomig (zolmitriptan) Tablets 2.5 mg & Zomig (zolmitriptan) Rapid Melt (RM) Tablets 2.5 mg

* Upsher-Smith Labs - ‍under agreement, Sawai expected to take manufacturing, marketing of Zomig​ products in Japan by mid-2018 from AstraZeneca K.K Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below